The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Open accessAbstract
Direct intralesional injection of specific or even generic agents, has been proposed over the years as cancer immunotherapy, in order to treat cutaneous or subcutaneous metastasis. Such treatments usually induce an effective control of disease in injected lesions, but only occasionally were able to demonstrate a systemic abscopal effect on distant metastases. The usual availability of tissue for basic and translational research is a plus in utilizing this approach, which has been used in primis for the treatment of locally advanced melanoma. Melanoma is an immunogenic tumor that could often spread superficially causing in-transit metastasis and involving draining lymph nodes, being an interesting model to study new drugs with different modality of administration from normal available routes. Talimogene laherperepvec (T-VEC) is an injectable modified oncolytic herpes virus being developed for intratumoral injection, that produces granulocyte-macrophage colony-stimulating factor (GM-CSF) and enhances local and systemic antitumor immune responses. After infection, selected viral replication happens in tumor cells leading to tumor cell lysis and activating a specific T-cell driven immune response. For this reason, a probable synergistic effect with immune checkpoints inhibition have been described. Pre-clinical studies in melanoma confirmed that T-VEC preferentially infects melanoma cells and exerts its antitumor activity through directly mediating cell death and by augmenting local and even distant immune responses. T-VEC has been assessed in monotherapy in Phase II and III clinical trials demonstrating a tolerable side-effect profile, a promising efficacy in both injected and uninjected lesions, but a mild effect at a systemic level. In fact, despite improved local disease control and a trend toward superior overall survival in respect to the comparator GM-CSF (which was injected subcutaneously daily for two weeks), responses as a single agent therapy have been uncommon in patients with visceral metastases. For this reason, T-VEC is currently being evaluated in combinations with other immune checkpoint inhibitors such as ipilimumab and pembrolizumab, with interesting confirmation of activity even systemically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988 · cited 1×
“The issue is to increase intratumoral infiltration by CD8+ T-cells, leading to their neoantigen’s recognition and tumor specificity strengthening, in order to being able to reverse the primary resistance to blockade therapy [45,67].”
BackgroundZea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7379 · Cited by 631
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 540
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
Andtbacka, R. H. I., Collichio, F., Harrington, K. J., Middleton, M. R., Downey, G., Ӧhrling, K., & Kaufman, H. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0623-z · Cited by 455
BCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience
MORTON, D. L., EILBER, F. R., HOLMES, E. C., HUNT, J. S., KETCHAM, A. S., SILVERSTEIN, M. J., & SPARKS, F. C. (1974) · Annals of Surgery · doi:10.1097/00000658-197410000-00029 · Cited by 449
Intratumoral immunotherapy: using the tumor as the remedy
Marabelle, A., Tselikas, L., de Baere, T., & Houot, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx683 · Cited by 375
Andtbacka, R. H. I., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K. A., Amatruda, T., Zager, J. S., Cranmer, L., Hsueh, E., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5286-0 · Cited by 308
Kohlhapp, F. J., & Kaufman, H. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2667 · Cited by 303
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Engeland, C. E., Grossardt, C., Veinalde, R., Bossow, S., Lutz, D., Kaufmann, J. K., Shevchenko, I., Umansky, V., Nettelbeck, D. M., Weichert, W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.160 · Cited by 280
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma
Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015) · Immunotherapy · doi:10.2217/imt.15.35 · Cited by 203
Guo, Z. S., Thorne, S. H., & Bartlett, D. L. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.02.001 · Cited by 192
Schuster, M., Nechansky, A., & Kircheis, R. (2006) · Biotechnology Journal · doi:10.1002/biot.200500044 · Cited by 179
Intratumoral Immunotherapy—Update 2019
Hamid, O., Ismail, R., & Puzanov, I. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0438 · Cited by 161
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
Thompson, J. F., Agarwala, S. S., Smithers, B. M., Ross, M. I., Scoggins, C. R., Coventry, B. J., Neuhaus, S. J., Minor, D. R., Singer, J. M., & Wachter, E. A. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4169-5 · Cited by 152
Weide, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T., Radny, P., Zelba, H., Pföhler, C., Pawelec, G., & Garbe, C. (2010) · Cancer · doi:10.1002/cncr.25156 · Cited by 148
Patinote, C., Karroum, N. B., Moarbess, G., Cirnat, N., Kassab, I., Bonnet, P., & Deleuze‐Masquéfa, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112238 · Cited by 138
Maynard, C. L., Hatton, R. D., Helms, W. S., Oliver, J. R., Stephensen, C. B., & Weaver, C. T. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20080950 · Cited by 118
Topical pharmacotherapy for skin cancer
Micali, G., Lacarrubba, F., Nasca, M. R., Ferraro, S., & Schwartz, R. A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.037 · Cited by 116
Moesta, A. K., Cooke, K. S., Piasecki, J., Mitchell, P., Rottman, J. B., Fitzgerald, K. L., Zhan, J., Yang, B., Le, T., Belmontes, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0681 · Cited by 110
Talimogene Laherparepvec: Review of its Mechanism of Action and Clinical Efficacy and Safety
Raman, S. S., Hecht, J. R., & Chan, E. (2019) · Immunotherapy · doi:10.2217/imt-2019-0033 · Cited by 109
Harrington, K. J., Andtbacka, R. H. I., Collichio, F. A., Downey, G. F., Chen, L., Szabó, Z. R., & Kaufman, H. L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s115245 · Cited by 104
Perez, M. C., Miura, J. T., Naqvi, S. M. H., Kim, Y., Holstein, A. H., Lee, D. H., Sarnaik, A. A., & Zager, J. S. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6803-0 · Cited by 101
Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
Louie, R. J., Perez, M. C., Jajja, M. R., Sun, J. X., Collichio, F. A., Delman, K. A., Lowe, M., Sarnaik, A. A., Zager, J. S., & Ollila, D. W. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.12.027 · Cited by 99
Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita, M., Tachibana, M., Dhar, D. K., Kotoh, T., Kinugasa, S., Kubota, H., Masunaga, R., & Nagasue, N. (1999) · PubMed · Cited by 82
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Dummer, R., Höeller, C., Grüter, I. P., & Michielin, O. A. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1967-1 · Cited by 71
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Hamid, O., Hoffner, B., Gasal, E., Hong, J. J., & Carvajal, R. D. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2025-8 · Cited by 70
Andtbacka, R. H. I., Ross, M. I., Agarwala, S. S., Taylor, M. H., Vetto, J. T., Neves, R. I., DAUD, A. I., Khong, H. T., Ungerleider, R. S., Tanaka, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9510 · Cited by 57
Treatment of metastatic melanoma with electrochemotherapy
Campana, L. G., Testori, A., Mozzillo, N., & Rossi, C. R. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23512 · Cited by 56
Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
Chaurasiya, S., Fong, Y., & Warner, S. G. (2020) · Cancers · doi:10.3390/cancers12061699 · Cited by 49
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Cancer vaccines: Building a bridge over troubled waters
Sellars, M. C., Wu, C. J., & Fritsch, E. F. (2022) · Cell · doi:10.1016/j.cell.2022.06.035 · Cited by 318
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 270
GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
Kumar, A., Taghi Khani, A., Sanchez Ortiz, A., & Swaminathan, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901277 · Cited by 265
Metadata
- Authors
- Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-03-18
- Volume
- 13
- Issue
- 6
- Pages
- 1383
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3137403642
- Cited by
- 317
- References
- 54
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.